Serum anti-GAPDH autoantibody levels reflect the severity of cervical lesions: A potential serum biomarker for cervical cancer screening
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Xu, Mei Ling | - |
dc.contributor.author | Kim, Hyoung Jin | - |
dc.contributor.author | Kim, Seung Cheol | - |
dc.contributor.author | Ju, Woong | - |
dc.contributor.author | Kim, Yun Hwan | - |
dc.contributor.author | Chang, Kyu-Ho | - |
dc.contributor.author | Kim, Hong-Jin | - |
dc.date.available | 2019-08-09T07:57:03Z | - |
dc.date.issued | 2019-07 | - |
dc.identifier.issn | 1792-1074 | - |
dc.identifier.issn | 1792-1082 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/32706 | - |
dc.description.abstract | Recent studies have indicated that a certain level of autoantibodies may be essential for maintaining good health as well as preventing cancer development, and that the levels of serum autoantibodies can decline during malignant progression. The aim of the present study was to identify such an autoantibody-based biomarker for screening cervical lesions. An autoantigen reactive with healthy female sera was detected in the cytosolic fraction of HeLa cells, a cervical cancer cell line, and identified. Serum immunoglobulin (Ig)-G and IgM levels against the purified autoantigen in normal, cervical intraepithelial neoplasias (CINs) I, II and III, and cervical cancer were compared using ELISAs. The autoantigen in HeLa cells was identified to be GAPDH. The serum levels of anti-HeLa-GAPDH IgG decreased with increasing severity of cervical lesions, and similar decreases in IgM levels were revealed. Notably, the anti-HeLa-GAPDH IgG level was discovered to discriminate cervical cancer from normal samples with 80.0% sensitivity and 96.6% specificity. The serum anti-HeLa-GAPDH autoantibody level, as a single parameter, is a promising serum biomarker for screening cervical lesions. | - |
dc.format.extent | 10 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | SPANDIDOS PUBL LTD | - |
dc.title | Serum anti-GAPDH autoantibody levels reflect the severity of cervical lesions: A potential serum biomarker for cervical cancer screening | - |
dc.type | Article | - |
dc.identifier.doi | 10.3892/ol.2019.10326 | - |
dc.identifier.bibliographicCitation | ONCOLOGY LETTERS, v.18, no.1, pp 255 - 264 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000474896900031 | - |
dc.identifier.scopusid | 2-s2.0-85068888685 | - |
dc.citation.endPage | 264 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 255 | - |
dc.citation.title | ONCOLOGY LETTERS | - |
dc.citation.volume | 18 | - |
dc.type.docType | Article | - |
dc.publisher.location | 그리이스 | - |
dc.subject.keywordAuthor | autoantibody | - |
dc.subject.keywordAuthor | glyceraldehyde 3-phosphate dehydrogenase | - |
dc.subject.keywordAuthor | cervical cancer | - |
dc.subject.keywordAuthor | cervical intraepithelial neoplasia | - |
dc.subject.keywordAuthor | serum biomarker | - |
dc.subject.keywordPlus | GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE GENE | - |
dc.subject.keywordPlus | TUMOR-ASSOCIATED ANTIGENS | - |
dc.subject.keywordPlus | HUMAN-PAPILLOMAVIRUS | - |
dc.subject.keywordPlus | NATURAL-HISTORY | - |
dc.subject.keywordPlus | RADICAL HYSTERECTOMY | - |
dc.subject.keywordPlus | IGM ANTIBODIES | - |
dc.subject.keywordPlus | SURVIVAL RATE | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | RISK | - |
dc.subject.keywordPlus | PROLIFERATION | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.